Exceptional Responders With Solid Tumor Cancer to Chemotherapy

Part of paid clinical trials in Los Angeles, California.

Sponsor
Adera Labs, LLC
Study ID
NCT02555735
Status
Enrolling By Invitation

Conditions

  • Solid Tumor Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Standard of Care Chemotherapy — DRUG
    Physician's Choice Chemotherapy Treatment (non-guided)

Study Details

This is an observational study enrolling patients with Solid Tumor cancers to identify genomic expression differences between exceptional responders and non-responders to standard of care chemotherapy. Data analysis of the gene expression profile of the exceptional responders compared to non-responders will define genomic patterns that may help understand their response to chemotherapy.

Key Dates

Start date
Oct 31, 2015
Status verified
Jan 2023
Primary completion
Dec 31, 2026
Completion
Aug 31, 2027

Study Design

Enrollment
250 participants (estimated)

Arms

  • Arm: Solid Tumor Cancer
    Participants with solid tumor cancer treated with physician-choice standard of care chemotherapy.

Primary Outcome Measure

Identify exceptional responders with cancer to standard of care chemotherapy [ Time Frame: 9 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
The Pancreatic Cancer Treatment Center of Los AngelesLos AngelesCalifornia90024-

Find similar trials in Los Angeles, CA

By research site
The Pancreatic Cancer Treatment Center of Los Angeles· Los Angeles, CA